Upstream therapeutic strategies of valsartan and fluvastatin on hypertensive patients with non ‐permanent atrial fibrillation
ConclusionsCCB plus fluvastatin and valsartan can reduce the recurrence rate of non ‐permanent AF and to delay the progression from non‐permanent AF to permanent AF in patients with hypertension. The combined application of valsartan and fluvastatin is more effective than valsartan or CCB alone in the upstream therapies of AF.
Source: Cardiovascular Therapeutics - Category: Cardiology Authors: Zhiqiang Zhao,
Xiaowei Niu,
Zhaojie Dong,
Wenwei Qi,
Enzhao Liu,
Tong Liu,
Lifeng Li,
Yingzi Liang,
Guangping Li Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
More News: Atrial Fibrillation | Brain | Cardiology | Cardiovascular | China Health | Diovan | Fluvastatin | Heart | Hypertension | Liver | Neurology | Statin Therapy | Study | Urology & Nephrology